Linked Data API

Show Search Form

Search Results

1712928
registered interest false more like this
date less than 2024-04-17more like thismore than 2024-04-17
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Mental Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps she is taking to improve access to mental health services. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 902442 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-24more like thismore than 2024-04-24
answer text <p>We have been expanding and transforming mental healthcare</p><p><br>In 2022/23 3.6 million people received secondary mental healthcare, and 1.2 million people accessed NHS talking therapies</p><p><br>This is an increase in the number of people receiving NHS mental health support of around 30% in just three years.</p> more like this
answering member constituency Faversham and Mid Kent more like this
answering member printed Helen Whately more like this
question first answered
less than 2024-04-24T08:22:40.02Zmore like thismore than 2024-04-24T08:22:40.02Z
answering member
4527
label Biography information for Helen Whately more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1684390
registered interest false more like this
date less than 2024-01-23more like thismore than 2024-01-23
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Food Standards Agency more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the adequacy of the resources provided to the Food Standards Agency to assess food safety applications. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 11130 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-01-30more like thismore than 2024-01-30
answer text <p>The Food Standards Agency regularly review their resources across the teams who are responsible for delivering the regulated products service and assessing food safety applications. The teams have expanded since they took over responsibility for the delivery of the service from the European Union in January 2021. However, as highlighted in their most recent Board paper in December 2023, resource pressure remains the main risk to their delivery timetables. In the short-term they are mitigating this risk through continuous improvements that enable the current system to work more efficiently within existing resources. In the longer-term they will bring forward plans for more fundamental reform to streamline the system and reduce the burden on applicants and the regulator, without compromising food safety.</p> more like this
answering member constituency South Northamptonshire more like this
answering member printed Andrea Leadsom more like this
question first answered
less than 2024-01-30T17:17:39.87Zmore like thismore than 2024-01-30T17:17:39.87Z
answering member
4117
label Biography information for Andrea Leadsom more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1682489
registered interest false more like this
date less than 2024-01-16more like thismore than 2024-01-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Rare Diseases: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential impact of the (a) methods and (b) processes used by the National Institute for Health and Care Excellence on access to medicines for patients with rarer diseases since January 2022; and whether this assessment will be reflected in the next Rare Diseases Action Plan for England. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 9850 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-01-23more like thismore than 2024-01-23
answer text <p>The National Institute for Health and Care Excellence (NICE) can recommend most rare disease medicines that it appraises through the technology appraisal programme for some or all eligible patients. NICE has no current plans to undertake a modular update of its methods and processes related specifically to rare diseases.</p><p> </p><p>NICE specifically considered treatments for rare diseases during its methods review, and many of the changes introduced in NICE’s updated health technology evaluation manual in January 2022 will benefit treatments for rare diseases. These include the severity modifier, flexibility in uncertainty considerations and the emphasis on a comprehensive evidence base including real-world, qualitative, surrogate and expert evidence. These updates seek to mitigate the barriers faced by rare disease technologies while maintaining an evidence-based, robust and proportionate evaluation approach.</p><p> </p><p>The 2022 England Rare Diseases Action Plan was published following the NICE methods and processes review. The 2022 Action Plan includes actions to capitalise on the changes made to NICE’s methods and processes to ensure that NICE continues to support the rapid adoption of effective new treatments for National Health Service patients with rare diseases. The impact of these changes is being assessed and an update will be provided in the 2024 England Rare Diseases Action Plan.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN 9851 more like this
question first answered
less than 2024-01-23T09:25:27.133Zmore like thismore than 2024-01-23T09:25:27.133Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1682490
registered interest false more like this
date less than 2024-01-16more like thismore than 2024-01-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading National Institute for Health and Care Excellence: Rare Diseases more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether she has had discussions with the National Institute for Health and Care Excellence on the case for a rarity modifier in its standard technology appraisal programme as part of its modular updates to its methods and processes. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 9851 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-01-23more like thismore than 2024-01-23
answer text <p>The National Institute for Health and Care Excellence (NICE) can recommend most rare disease medicines that it appraises through the technology appraisal programme for some or all eligible patients. NICE has no current plans to undertake a modular update of its methods and processes related specifically to rare diseases.</p><p> </p><p>NICE specifically considered treatments for rare diseases during its methods review, and many of the changes introduced in NICE’s updated health technology evaluation manual in January 2022 will benefit treatments for rare diseases. These include the severity modifier, flexibility in uncertainty considerations and the emphasis on a comprehensive evidence base including real-world, qualitative, surrogate and expert evidence. These updates seek to mitigate the barriers faced by rare disease technologies while maintaining an evidence-based, robust and proportionate evaluation approach.</p><p> </p><p>The 2022 England Rare Diseases Action Plan was published following the NICE methods and processes review. The 2022 Action Plan includes actions to capitalise on the changes made to NICE’s methods and processes to ensure that NICE continues to support the rapid adoption of effective new treatments for National Health Service patients with rare diseases. The impact of these changes is being assessed and an update will be provided in the 2024 England Rare Diseases Action Plan.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN 9850 more like this
question first answered
less than 2024-01-23T09:25:27.177Zmore like thismore than 2024-01-23T09:25:27.177Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1682492
registered interest false more like this
date less than 2024-01-16more like thismore than 2024-01-16
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Cost Benefit Analysis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with (a) HM Treasury and (b) the National Institute for Health and Care Excellence on the adoption of a discount rate of 1.5% when assessing the future (a) benefits and (b) costs of medicines to align with the guidance set out in the Green Book. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 9852 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-01-19more like thismore than 2024-01-19
answer text <p>The Department of Health and Social Care has had a number of discussions with HM Treasury and the National Institute for Health and Care Excellence (NICE) about the discount rate used in the evaluation of medicines, including as part of the 2022 review of NICE’s methods and processes for health technology evaluation.</p><p>Through the methods review, NICE concluded that it was appropriate to maintain the reference case discount rate of 3.5% and has retained the flexibility in its methods for its committees to apply a lower non-reference case discount rate of 1.5% per year for both cost and health effects in exceptional circumstances. The decision on whether a non-reference case discount rate should be applied is taken by NICE’s Appraisal Committees.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-01-19T10:08:46.7Zmore like thismore than 2024-01-19T10:08:46.7Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1671599
registered interest false more like this
date less than 2023-11-20more like thismore than 2023-11-20
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Meat more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether the Food Standards Agency has made an assessment of the potential impact of changing the legal definition of wishbone meat. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 2601 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-11-27more like thismore than 2023-11-27
answer text <p>There is no legal definition of wishbone meat. The Food Standards Agency has not made an assessment of the potential impact of introducing such a legal definition.</p> more like this
answering member constituency South Northamptonshire more like this
answering member printed Andrea Leadsom more like this
question first answered
less than 2023-11-27T17:12:00.527Zmore like thismore than 2023-11-27T17:12:00.527Z
answering member
4117
label Biography information for Andrea Leadsom more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1667694
registered interest false more like this
date less than 2023-11-07more like thismore than 2023-11-07
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Chronic Fatigue Syndrome: Research more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that funding for biomedical research into myalgic encephalomyelitis (ME) is adequate; and whether he plans to take steps to establish a centre of excellence on ME to (a) promote understanding of and (b) develop effective treatments for that illness. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 236 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-11-17more like thismore than 2023-11-17
answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR has provided around £4.4 million of programme funding for research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) since 2011.</p><p>Through the NIHR, the Department has co-funded, with the Medical Research Council (MRC) a £3.2 million study called DecodeME into the genetic underpinning of ME/CFS. The study will analyse samples from 25,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or an increased risk of developing the condition. This study aims to increase our understanding of the disease and therefore contribute to the research base on diagnostic tests and targeted treatments for ME/CFS.</p><p>The Department and the NIHR has no specific plans to establish a centre of excellence for ME research. The NIHR welcomes funding applications for research into any aspect of human health, including biomedical research for ME/CFS. These applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2023-11-17T12:25:59.07Zmore like thismore than 2023-11-17T12:25:59.07Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1667713
registered interest false more like this
date less than 2023-11-07more like thismore than 2023-11-07
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Novel Foods: Regulation more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to page 20 of his Department's food strategy white paper, published on June 2022, what his planned timetable is for when the Food Standards Agency will review the novel foods regulatory framework. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 238 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-11-16more like thismore than 2023-11-16
answer text <p>The Food Standards Agency (FSA) is committed to maintaining the United Kingdom’s high standards of food and feed safety whilst also working hard to support innovation across the food system. The FSA has a programme of continuous improvement and reform that has been in place since the launch of the Regulated Products Service in January 2021.</p><p> </p><p>In June, the FSA published a summary of the findings of the review of the Novel Foods Regulatory Framework. Following this review, the FSA has focused resource to look at potential future options for more fundamental reform of the food and feed regulatory system. This has included surveying stakeholders across all regulated product regimes to gain their views on potential reforms.</p><p> </p><p>The FSA is in the process of analysing this information to develop reform plans and will provide further detail on these, including timetables, at the public FSA Board meetings in the future.</p> more like this
answering member constituency South Northamptonshire more like this
answering member printed Andrea Leadsom more like this
question first answered
less than 2023-11-16T12:23:41.25Zmore like thismore than 2023-11-16T12:23:41.25Z
answering member
4117
label Biography information for Andrea Leadsom more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1667714
registered interest false more like this
date less than 2023-11-07more like thismore than 2023-11-07
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Novel Foods: Regulation more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to his Department's food strategy white paper, published on June 2022, what steps the Food Standards Agency is taking to help food producers conduct (a) safe and (b) limited tastings of novel food products. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 239 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-11-16more like thismore than 2023-11-16
answer text <p>Under retained EU Regulation 2015/2283, a novel food is only deemed safe to be placed on the market in Great Britain after the Food Standards Agency (FSA) has processed an application for the authorisation of the novel food.</p><p> </p><p>For foods that are still in the research and development phase prior to authorisation guidance issued by the FSA Advisory Committee on Novel Foods and Processes in 2002 confirms that taste trials are permitted as long as they are not conducted for marketing or advertising purposes.</p> more like this
answering member constituency South Northamptonshire more like this
answering member printed Andrea Leadsom more like this
question first answered
less than 2023-11-16T12:37:36.21Zmore like thismore than 2023-11-16T12:37:36.21Z
answering member
4117
label Biography information for Andrea Leadsom more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter
1667715
registered interest false more like this
date less than 2023-11-07more like thismore than 2023-11-07
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Novel Foods more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to the Answer of 12 December 2022 to Question 105459 on Food: Research, what progress the Food Standards Agency has made in developing dedicated guidance materials for alternative protein companies developing novel foods and processes; and when he plans to publish that guidance. more like this
tabling member constituency Cambridge more like this
tabling member printed
Daniel Zeichner more like this
uin 240 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2023-11-16more like thismore than 2023-11-16
answer text <p>The Food Standards Agency (FSA) has prepared an information page for its website that will provide guidance to companies producing cell-cultivated products that wish to apply for regulatory approval. This will be published before the end of November 2023.</p><p> </p><p>This page will outline information about the FSA’s regulated product application service, the regulations that apply to these cell-cultivated products, and information about labelling implications. Alongside this, the FSA has been providing pre-application support to businesses on an individual basis due to the novelty and complexity of this technology. This one-to-one engagement with business and industry has helped to inform and tailor our online guidance which will be available shortly.</p><p> </p><p>The FSA is also considering producing additional regulatory guidance for alternative protein producers as part of its wider aim to support business innovation whilst ensuring that food is safe and what it says it is. In addition to this, a new UK Research and Innovation project was announced on 9 November 2023 that will work on new safety rules for the United States of America, Singapore, United Kingdom and the European Union with a focus on creating standards for cell-cultivated protein.</p>
answering member constituency South Northamptonshire more like this
answering member printed Andrea Leadsom more like this
question first answered
less than 2023-11-16T12:39:36.593Zmore like thismore than 2023-11-16T12:39:36.593Z
answering member
4117
label Biography information for Andrea Leadsom more like this
tabling member
4382
label Biography information for Daniel Zeichner remove filter